NO20055536L - Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon - Google Patents

Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon

Info

Publication number
NO20055536L
NO20055536L NO20055536A NO20055536A NO20055536L NO 20055536 L NO20055536 L NO 20055536L NO 20055536 A NO20055536 A NO 20055536A NO 20055536 A NO20055536 A NO 20055536A NO 20055536 L NO20055536 L NO 20055536L
Authority
NO
Norway
Prior art keywords
individuals
procedures
renal function
impaired renal
diuresis
Prior art date
Application number
NO20055536A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055536D0 (no
Inventor
Kenneth J Widder
Lauren Otsuki
Howard Dittrich
Scott Thomson
Roland Blantz
Original Assignee
Novacardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacardia Inc filed Critical Novacardia Inc
Publication of NO20055536D0 publication Critical patent/NO20055536D0/no
Publication of NO20055536L publication Critical patent/NO20055536L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20055536A 2003-04-25 2005-11-23 Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon NO20055536L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46600703P 2003-04-25 2003-04-25
PCT/US2004/012518 WO2004096228A1 (en) 2003-04-25 2004-04-23 Method of improved diuresis in individuals with impaired renal function

Publications (2)

Publication Number Publication Date
NO20055536D0 NO20055536D0 (no) 2005-11-23
NO20055536L true NO20055536L (no) 2005-12-29

Family

ID=33418325

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055536A NO20055536L (no) 2003-04-25 2005-11-23 Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon

Country Status (16)

Country Link
US (3) US7579331B2 (pt)
EP (1) EP1620107A1 (pt)
JP (1) JP2006524699A (pt)
KR (1) KR20060004959A (pt)
CN (1) CN1859913A (pt)
AR (1) AR044069A1 (pt)
AU (1) AU2004233852A1 (pt)
BR (1) BRPI0409699A (pt)
CA (1) CA2522971A1 (pt)
MX (1) MXPA05011371A (pt)
NO (1) NO20055536L (pt)
NZ (1) NZ543109A (pt)
RU (1) RU2367442C2 (pt)
TW (1) TW200500070A (pt)
WO (1) WO2004096228A1 (pt)
ZA (1) ZA200509311B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
AU2004233852A1 (en) 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
JP2007504136A (ja) * 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
JP2007532671A (ja) * 2004-04-16 2007-11-15 ノヴァカーディア，インク． アデノシンａ１受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法
WO2006091716A2 (en) * 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
CN101166515A (zh) * 2005-04-22 2008-04-23 美国诺华卡迪亚公司 用于非水溶性药物成分静脉注射的乳剂的生产
JPWO2007069675A1 (ja) * 2005-12-14 2009-05-28 協和発酵キリン株式会社 キサンチン誘導体の易吸収性経口製剤
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
WO2007149283A2 (en) * 2006-06-16 2007-12-27 Novacardia, Inc. Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416810C (sv) 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
FR2531085A1 (fr) 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4769377A (en) 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
DE8817122U1 (de) 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
SE9000207L (sv) 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1993000081A1 (en) 1991-06-28 1993-01-07 Sepracor, Inc. Optically pure s(-) nadolol for treatment of cardiovascular disorders
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
TW252044B (pt) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
DE4238367A1 (de) 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
CN1049117C (zh) 1994-09-16 2000-02-09 赵明玉 预防和治疗偏头痛的偏头痛片
WO1997004782A1 (en) 1995-07-26 1997-02-13 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion or solid dispersion preparation of xanthine derivatives
ES2232877T3 (es) 1996-08-07 2005-06-01 Kyowa Hakko Kogyo Co., Ltd. Emulsion grasa que contiene un derivado de xantina.
US6187780B1 (en) 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20020115687A1 (en) 1998-04-24 2002-08-22 Evan Beckman Method and composition for restoring diuretic and renal function
AU3757999A (en) 1998-04-24 1999-11-16 Biogen, Inc. Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
CA2390496A1 (en) 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
PL198156B1 (pl) 1999-11-12 2008-05-30 Biogen Idec Ma Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna
US20050038017A1 (en) 1999-12-22 2005-02-17 Wolff Andrew A. Method and composition for restoring diuretic and renal function
UA75625C2 (en) 2000-12-01 2006-05-15 Biogen Inc Condensed purine derivatives as a1 adenosine receptor antagonists
MXPA03005462A (es) 2000-12-18 2003-09-25 Novartis Ag Combinacion terapeutica de amlodipina y benazepril.
UA80258C2 (en) 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US20040229901A1 (en) 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
AU2004233852A1 (en) 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
US20050070524A1 (en) 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
JP2007532671A (ja) 2004-04-16 2007-11-15 ノヴァカーディア，インク． アデノシンａ１受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法
CA2565037A1 (en) 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
CA2648281A1 (en) 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
EP2035009A1 (en) 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
WO2007149283A2 (en) 2006-06-16 2007-12-27 Novacardia, Inc. Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
CA2661044A1 (en) 2006-08-22 2008-02-28 Novacardia, Inc. Kw-3902 conjugates that do not cross the blood-brain barrier

Also Published As

Publication number Publication date
NZ543109A (en) 2008-06-30
CA2522971A1 (en) 2004-11-11
US7579331B2 (en) 2009-08-25
KR20060004959A (ko) 2006-01-16
US20060035911A1 (en) 2006-02-16
WO2004096228A1 (en) 2004-11-11
ZA200509311B (en) 2006-10-25
AR044069A1 (es) 2005-08-24
RU2005131938A (ru) 2006-06-27
TW200500070A (en) 2005-01-01
MXPA05011371A (es) 2005-12-01
JP2006524699A (ja) 2006-11-02
AU2004233852A1 (en) 2004-11-11
US20050004145A1 (en) 2005-01-06
US20060030572A1 (en) 2006-02-09
EP1620107A1 (en) 2006-02-01
NO20055536D0 (no) 2005-11-23
RU2367442C2 (ru) 2009-09-20
CN1859913A (zh) 2006-11-08
BRPI0409699A (pt) 2006-04-18

Similar Documents

Publication Publication Date Title
NO20082768L (no) Levodopa prodroge mesylat, sammensetninger og anvendelser derav
WO2008061226A3 (en) Sustained-release formulations of topiramate
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
CY1118179T1 (el) Φαρμακευτικη συνθεση
DK1638569T3 (da) Anvendelse af brimonidin til at forebygge og nedsætte alvorligheden af med stress forbundne tilstande
ECSP10010265A (es) Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil)
DE69629591D1 (de) Formulierung zur intranasalen verabreichung
FR2864958B1 (fr) Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
NO20074295L (no) Substituerte gamma lactamer som terapeutiske midler
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
NO20073403L (no) Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
WO2005027977A3 (en) Diclofenac compositions for the treatment of skin disorders
DE602005027540D1 (de) Feste formulierungen von ospemifen
WO2006102308A3 (en) Beta-lactamyl vasopressin v1b antagonists
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
SE0302488D0 (sv) New combination
NO20043834L (no) Farmasoytisk sammensetning omfattende N-((1-N-butyl-4-piperidinyl)metyl-3,4-dihydro-2H-(1,3)-oksazino(3,2-A)indol-l0-karboksyamid eller salter og fremgangsmate derfor omfattende torr granulering
TW200500070A (en) Method of improved diuresis in individuals with impaired renal function
EP1781277A4 (en) COMBINATION PREPARATION
JP2004505922A5 (pt)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application